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The main therapy in renal cell carcinoma (RCC) is operative treat-
ment but the operative results are variable (Sweeney et al, 1996;
Giberti et al, 1997). In a proportion of the cases, adjuvant treat-
ment may be helpful to improve the survival of patients. To iden-
tify the group of patients who may benefit from additional
treatment modalities, new accurate prognostic factors are urgently
needed. Today the TNM classification and nuclear grade are the
main factors on which the treatment decisions are based, but better
prognostic factors are under research to tailor the therapy individ-
ually. The knowledge and understanding of the biological nature
of RCC has increased and new promising prognostic indicators
have been already identified. These markers include indicators of
cell proliferation (Aaltomaa et al, 1997; Papadopoulos et al, 1997),
cell adhesion (Koga et al, 1997; Paul et al, 1998), markers
involved directly in the regulation of cell growth (Hofmockel et al,
1997; Shiina et al, 1997) and growth-stimulating or suppressing
gene products (Hofmockel et al, 1997; Shiina et al, 1997).
The suppressor gene p53 is frequently mutated in different
cancers and it is able to stop the cell cycle at G1 phase and also to
induce apoptosis. The recent reports suggest that p21(waf1/cip1) is a
main mediator of p53 tumour suppressor gene effects (EI Deiry
et al, 1995; Naka et al, 1998). Elevated levels of p21(waf1/cip1) protein
in response to both p53-dependent and -independent signals
mediate the cell cycle arrest predominantly at the G1 phase of the
cell cycle (Zeng et al 1996). p21(waf1/cip1) exerts this effect by
inhibiting the cyclin-dependent kinases (cdk) that are required to
drive the cell division cycle. While active cdk are found in normal
cells in a quaternary complex with cyclins, proliferating cell
nuclear antigen and p21(waf1/cip1), more than one molecule of
p21(waf1/cip1) per complex results in kinase inhibition (Waga et al,
1994; Zhang et al, 1994). In experimental analyses of human
bladder cancer cell lines p21(waf1/cip1) is able to induce apoptosis, but
the exact role of p21(waf1/cip1) in apoptosis is not completely under-
stood (Kawasaki et al, 1998). In RCC the significance of
p21(waf1/cip1) protein in tumour differentiation and patient survival
has not been previously studied. Cyclin A and D1 are protein
kinases related to control of the cell cycle and cell proliferation
(Donnellan and Chetty, 1998). Cyclins act together with the cdk by
phosphorylating the main substrates responsible for the cell cycle
regulation (Donnellan and Chetty, 1998). Phosphorylation of the
retinoblastoma (Rb) tumour suppressor protein (pRB) by the
complexes of cyclins and cdk makes Rb protein active to induce
genes controlling cell proliferation, thus being a part of the control
of the cell cycle machinery (Strauss et al, 1995; Donnellan and
Chetty, 1998). Cyclin D1 is most active in G1 resting phase before
S-phase by regulating the DNA synthesis, by phosphorylating the
pRB and simultaneously activating its function (Strauss et al,
1995; Donnellan and Chetty, 1998). Cyclin A regulates the cell
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1998). The overexpression of cyclins has been related to high
proliferation rate of the tumour cells and to other unfavourable
prognostic factors, although the results are not uniform (Aaltomaa
et al, 1999a; Donnellan and Chetty, 1998; Ishikawa et al, 1998;
Maeda et al, 1998; Volm et al, 1998). The gene amplification and
protein expressions of cyclins A and D1 have been previously
studied in several human epithelial neoplasms to establish their
possible prognostic significance in clinical human cancer
(Barbareschi et al, 1997; Michalides et al, 1997; Aaltomaa et al,
1999a; Donnellan and Chetty, 1998; Maeda et al, 1998; Volm et al,
1998). At present there are no reports available on the prognostic
value of the expressions of cyclins A and D1 in RCC.
The aims of our study were to analyse the expressions of cyclins
A and D1 as well as p21 (waf1/cip1) protein in RCC and to compare
the expressions of these proteins to other clinical and histopatho-
logical parameters, and to establish the prognostic value of these
proteins in RCC patients.
PATIENTS AND METHODS
The study includes 118 RCC patients treated between 1968 and
1985 and followed up to 1991 at the Department of Surgery,
Kuopio University Hospital, Finland. The cohort was not entirely
consecutive since adequate biopsy specimens for immunohisto-
chemistry were not available in all cases. The estimated total
number of diagnosed RCCs during the enrolment period was about
200 cases, but an operation was carried out in only about half of
the cases. The mean (range) age of the patients at diagnosis was 61
(range 22–82) years and the mean (range) follow-up time was 9.7
(range 5.3–20.2) years. The follow-up of patients after therapy
lasted until death or to the year 1991. The diagnosis, clinical
staging, treatment and clinical follow-up were carried out mainly
by two urologists. The diagnosis was based on the results of
routine laboratory tests and intravenous (i.v.) urography, and on
ultrasonography and computerized tomography (CT) during the
last years of follow-up. The histological confirmation was needed
before the diagnosis was settled. In addition, the bone chart, chest
X-ray and ultrasonography were done to detect the possible metas-
tasis. During the first 2 years the follow-up was done on every 3rd
month and thereafter every 6th month up to 5 years, and after that
controls were started once a year. During the follow-up, routine
laboratory tests and chest X-rays were done on regular basis, and
ultrasonography, i.v. urography, CT and the bone chart when they
were indicated. There were 114 cases treated with radical nephrec-
tomy, in four cases a partial nephrectomy was done. The causes of
death were verified from the patient files, death certificates and
from the files of the Finnish Cancer Registry.
Histological methods
Five micrometer-thick serial sections were cut from the paraffin-
embedded surgical specimens and stained with haematoxylin and
eosin. The samples were examined in a blinded manner. Tumours
were categorized into four nuclear grades as described in detail in
the previous literature (Syrjänen and Hjelt, 1978). The mitotic
figures were identified, usually at the tumour periphery at the areas
of the most proliferative and invasive growth. The counting of
mitotic figures was done by using an objective magnification of 40
´ (field diameter 490 mm) and the volume corrected mitotic index
(M/V) method was used (Haapasalo et al, 1989). The M/V index
expresses the number of mitotic figures mm–2 of neoplastic
epithelium in the section. The mean M/V index was 6.9 (standard
deviation (s.d.) range 0–44) mm–2.
Cyclin A and D1 and p21(waf1/cip1) immunohistochemistry
Cyclin A (Aaltomaa et al, 1998a) was demonstrated by a routine
immunohistochemical method, which is similar to that described
in connection with Ki-67 immunostaining except that microwave
pretreatment was not used in cyclin A immunohistochemistry. The
antibody was purchased from Novocastra Laboratories (Newcastle
upon Tyne, UK) and it was used at a dilution of 1:200. Cyclin D1
(Aaltomaa et al, 1999a) and p21(waf1/cip1) (Lipponen et al, 1998)
were demonstrated by using the same staining procedure as
described in connection with Ki-67 immunohistochemistry
(Aaltomaa et al, 1997). Both of the antibodies were purchased
from Novocastra Laboratories (Newcastle upon Tyne, UK) and
they were used at a dilution of 1:100 (cyclin D1) and 1:20
(p21(waf1/cip1)). The expressions of cyclins and p21(waf1/cip1) (fraction
of positive tumour cells) were evaluated in the entire section
(magnification 400 ´). The expression of cyclin D1 was consid-
ered positive only when distinct strong nuclear positivity was
present. Faint expression of cyclin D1 was present in most of the
cancers, but it was not included in the scoring process as recom-
mended in the previous literature (Gillet et al, 1996). The mean
(s.d.) fractions of cyclin A- and D1-positive nuclei were 2.2%
(s.d. 4.1%) and 23.2% (s.d. 28.7%) respectively. The mean (s.d.)
fraction of positive nuclei for p21(waf1/cip1) was 6.8% (s.d. 10.5%).
Ki-67 immunohistochemistry
For immunohistochemical demonstration of Ki-67 protein, 5-mm
sections were deparaffinized, rehydrated and washed for 5 min
with phosphate-buffered saline (PBS). Thereafter the sections
were rinsed in distilled water and heated in a microwave oven for
2 ´ 5 min in 0.01 M citrate buffer (pH 6.0). After that the slides
were rinsed in Tris-buffered saline (pH 7.4). Endogenous peroxide
was blocked by 3% hydrogen peroxide for 5 min followed by a
wash for 5 min with PBS. The tissue sections were incubated with
the monoclonal anti-Ki-67 protein (MIB1, Dianova Marseille,
France) antibody diluted at 1:100 in PBS. Sections were washed
twice for 5 min with PBS, incubated for 20 min with biotinylated
secondary antibody (Vectastain ABC Elite Kit, Vector
Laboratories, CA, USA) diluted at 1:200 in PBS. Slides were
washed twice in PBS for 10 min and incubated for 20 min in
preformed avidin–biotinylated peroxidase complex (Vectastain
ABC Elite Kit, Vector Laboratories, CA, USA). Sections were
washed twice for 5 min with PBS, developed with diaminobenzi-
dine tetrahydrochloride substrate (Sigma Chemical Co., St Louis,
MO, USA), slightly counterstained with Mayer’s haematoxylin,
dehydrated, cleared and mounted. Normal human tonsil was used
as a positive control. The fraction of positively stained nuclei was
estimated in the area of the tumour that contained the highest
fraction of Ki-67-positive cells. The mean (s.d.) fraction of Ki-67
positive nuclei was 14.2% (s.d. 15.7%).
p53 and PCNA immunohistochemistry
The expression of these proteins was detected by a routine
immunohistochemical method as detailed in previous literature
(Lipponen et al, 1994). The antibody for p53 (CM1, Novocastra
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1:1200. The antibody for PCNA (PC10) was purchased from
DAKO (Golstrup, Denmark) and it was used at a dilution of 1:100.
The fraction of positive cells was analysed from the areas with the
highest fraction of positive cells as detailed before (Lipponen et al,
1994). The mean (s.d.) fraction of p53-positive cells was 1.2%
(s.d. 7.6%) and of proliferating cell nuclear antigen (PCNA)
29.3% (s.d. 30.4%).
Statistical methods
In statistical calculations, the SPSS-X was used in an IBM
computer and the statistical tests used are indicated in the results
when appropriate. Univariate survival analysis was done by the
SPSS-X using the Kaplan–Meier method with statistics by Gehan.
Multivariate survival analysis (Cox’s analysis) was done in a step-
wise manner. Survival analysis included (as an event) only the
deaths due to renal cell carcinoma. During the follow-up, 68
patients died of renal cell carcinoma and three died from other
causes. When the disease-free survival was analysed, only M0
cases (n = 82) were included in the analysis. The group limits
(when categorized data is used) for Ki-67, p53 and PCNA were set
so that these parameters showed the highest possible correlation to
cyclin A, D and p21(waf1/cip1) expression in Table II.
RESULTS
Cyclins A or D1 and p21(waf1/cip1) were not expressed in normal
renal tissue adjacent to tumours. The positive stainings of cyclin
D1 (Figure 1A) and p21(waf1/cip1) (Figure 1B) were confined to the
tumour cell nuclei, whereas cyclin A (Figure 1C) was also
expressed in the cytoplasm of the cancer cells. The staining pattern
of these proteins showed both intra- and intertumour variation.
The mean (range) fractions of cyclin A-, cyclin D1- and
p21(waf1/cip1)-positive cells were 2.2% (range 0–20%), 23.3% (range
0–90%) and 6.8% (range 0–70%), respectively.
The expression of p21(waf1/cip1) was not related to nuclear grade
(P = 0.6), T-category (P = 0.7), M-category (P = 0.4), tumour size
(P = 0.8), patient age (P = 0.4) or venous invasion (P = 0.3).
The expression of cyclins A and D1 were not related to sex,
T-category, M-category or tumour size (P > 0.05), but the expres-
sion of cyclin A was related to venous invasion (P = 0.04) and
cyclin D to age over 65 years (P = 0.03). The relationship between
the histopathological parameters and cyclin A and D1 is shown in
Table 1. The expression of p21(waf1/cip1) protein was not related to
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Figure 1 (A) The staining of cyclin D1 was always nuclear. A high fraction
of cyclin D1-positive tumour cell nuclei in a poorly differentiated RCC
(magnification 250´). (B)The staining of p21(waf1/cip1) protein was nuclear. A
high fraction of positively stained tumour cell nuclei in RCC (magnification
250 ´). (C)The expression of cyclin A was both cytoplasmic and nuclear. A
high fraction of cyclin A-positive tumour cell nuclei in a poorly differentiated
RCC (magnification 250 ´)any of the parameters shown in Table 1. The correlation coeffi-
cients and their significance between the different histopatholog-
ical tumour markers are shown in Table 2.
Cyclin A predicted survival in the entire study group (P =
0.0014, Figure 2), in M0 (P = 0.0007, Figure 3) and in
T1–2/N0/M0 cases (P = 0.0007, Figure 4). It was also a powerful
predictor of disease-free survival in T1–4/N0/M0 (P = 0.0027) and
in T1–2/N0/M0 tumours (P = 0.0007). Cyclin D1 and p21(waf1/cip1)
were not significantly related to patient survival or disease-free
survival in any of the analysed subgroups. The independent prog-
nostic factors of survival are shown in Table 3.
DISCUSSION
Cyclins are closely related to cell cycle by acting together with cdk
in phosphorylating the Rb protein. Type D1 cyclin is mostly
expressed during the first gap phase (G1) of the cell cycle and it is
a major factor in the timing process of starting DNA synthesis in
mammalian cells (Strauss et al, 1995; Kato, 1997; Donnellan and
Chetty, 1998). On the contrary, cyclin A is expressed mainly in
late S and G2 phases and is degraded during mitotic phase before
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Table 1 The relationship between the fraction of cyclin A- and D1-positive cells and other prognostic factors in renal cell carcinoma
Variable Number Cyclin A-positive cells  P-valuea Cyclin D1-positive cells P-valuea
mean (s.d.) mean (s.d.)
NG 1 30 0.8 (2.7) 33.4 (34.7)
NG 2 54 1.5 (3.2) 22.4 (26.8)
NG 3 34 4.7 (5.4) 0.0002 15.4 (24.4) 0.042
M/V ≤ 7/mm2 84 1.4 (3.5) 26.1 (29.6)
M/V > 7/mm2 34 4.3 (4.8) 0.002 16.2 (25.5) 0.09
Ki 67 < 1% 17 0.1 (0.1) <0.001 24.4 (33.4)
Ki 67 > 1% 92 2.6 (4.2) 22.8 (27.9) 0.8
PCNA < 5% 48 1.1 (3.1) 0.006 27.3 (31.9)
PCNA > 5% 63 3.2 (4.8) 20.6 (27.2) 0.2
p53 < 1% 101 2.4 (4.4) 0.4 21.3 (28.0)
p53 > 1% 10 1.4 (2.1) 46.0 (35.2) 0.01
p21 < 1% 43 1.7 (3.9) 0.3 13.6 (24.4)
p21 > 1% 75 2.6 (4.3) 28.7 (29.7) 0.005
NG, nuclear grade; M/V, volume corrected mitotic index; PCNA, proliferating cell nuclear antigen. aTwo groups: t-test; three groups:
analysis of variance.
Table 2 The correlation coefficients and their significance between the different histopathological tumour markers.
M/V Kl-67 PCNA p53 Cyclin A Cyclin D1
Cyclin A 0.4574 0.6295 0.4304 –0.0438
P = 0.235 P = 0.000 P = 0.000 P = 0.648
Cyclin D1 –0.1359 –0.1659 –0.2078 0.0338 –0.104
P = 0.142 P = 0.085 P = 0.029 P = 0.725 P = 0.25
p21 0.1009 0.1668 0.1200 –0.0693 0.0547 0.2334
P = 0.277 P = 0.083 P = 0.210 P = 0.470 P = 0.556 P = 0.011
M/V index, mitotic index: PCNA, proliferating cell nuclear antigen.
Table 3 The independent prognostic factors (final step analysis) of survival
in multivariate analysis, which included all the analysed prognostic
parameters. Some of the parameters were not available in all cases and
accordingly the total number of cases included is lower than in the original
cohort
Variable RR Cl P-value
Entire cohort (n = 96)
Metastasis 5.16 2.71–9.83 <0.001
T-category 2.68 1.67–4.31 <0.001
Ki-67 1.02 1.00–1.04 0.026
Cyclin A 1.12 1.05–1.20 0.001
M0 tumours (n = 70)
T-category 2.67 1.48–4.84 0.001
Cyclin A 1.21 1.12–1.31 <0.001
Multivariate analyses included following variables: T-classification, node
status, presence of metastasis, nuclear grade, mitotic rate, Ki-67, cyclin A
and D1, p21(waf1/cip1), p53, proliferating cell nuclear antigen (PCNA), sex and
age. RR, risk ratio; Cl, 95% confidence interval.
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Figure 2 The survival of RCC patients categorized according to the fraction
of cyclin A-positive cancer cells in the entire study group. The curves are
significantly separated (c2 = 10.2, P = 0.0014). Curve A: the fraction of cyclin
A-positive cells ≤ 1%, n = 66; Curve B: the fraction of cyclin A-positive cells
> 1%, n = 47the metaphase (Donnellan and Chetty, 1998). The increased
expression of cyclins is related to disregulated or accelerated cell
cycle as a result of gene amplification, chromosomal translocation,
down- or up-regulated expression (Naitoh et al, 1995; Barbareschi
et al, 1997; Aaltomaa et al, 1999a; Volm et al, 1998). So far, no
previous study has compared the relationships between the expres-
sions of cyclins and p21(waf1/cip1), p53 as well as Ki-67 expressions
in RCC. Consequently, the prognostic role of cyclins in RCC has
not yet been defined.
Although in other carcinomas the relationship between TNM
classification and cyclins is obvious (Michalides et al, 1997;
Aaltomaa et al, 1999a), we could not find any correlation between
the expression of cyclin A and TNM categories. Differentiation
grade was significantly associated with the fraction of cyclin A-
positive cells, which is in line with the results from prostate cancer
as well (Aaltomaa et al, 1999a). The expression of cyclin A was
also related to many indicators of cell proliferation such as Ki-67
and PCNA expressions and mitotic rate, a finding which is in
accordance with previous reports (Marshall et al, 1996; Aaltomaa
et al, 1999a). The staining signal of cyclin A was independent of
p53 and p21(waf1/cip1) expressions, which suggests that these latter
proteins may be of minor importance in cell cycle control in RCC.
Additional support for this suggestion comes from the study
(Papandreou et al, 1997) in which the p21(waf1/cip1) gene was rarely
mutated in RCC.
Cyclin D1 was not related to TNM classification in RCC in the
present study. A high fraction of cyclin D1-positive cells was
linked with low cell proliferation and well-differentiated tumours.
There are no reports available in the literature to verify our results
in RCC, but in breast cancer the expression of cyclin D1 is related
to sex steroid receptor positivity and favourable histological signs
(Gillet et al, 1996; Barbareschi et al, 1997). Also, in bladder
cancer, the initial results suggest that cyclin D1 might be associ-
ated with low histological grade (Lee et al, 1997). The above
results in bladder and breast cancer are in accordance with our
results in RCC. However, the results are variable, since the close
relationship between overexpression of cyclin D1 and malignant
cellular prognostic features has been observed in other cancers
(Nakamura et al, 1997; Pignataro et al, 1998). In gastric and colon
cancer the strong expression of cyclin D1 is related to lymph node
involvement (Nakamura et al, 1997; Maeda et al, 1998), and in
ovarian cancer to tumour malignancy (Barbieri et al, 1997). In
addition, our analysis revealed a positive correlation (Table 2)
between the expression of p21(waf1/cip1) and cyclin D1. This associa-
tion is most probably due to reduced cell proliferation of cyclin
D1-positive tumours and possibly to growth inhibitory functions
of p21(waf1/cip1).
In RCC, the staining signal of p21(waf1/cip1) seems to be indepen-
dent of p53 expression. Indeed, p53 independent expression of
p21(waf1/cip1) has been reported in several tumour types, including
colon, endometrium, prostate and bladder cancer (Backe et al,
1997; Yasui et al, 1997; Aaltomaa et al, 1999b; Lipponen et al,
1998). Unexpectedly, p21(waf1/cip1) was not associated with the
expression of PCNA or other indicators of accelerated cell prolif-
eration, although in cells p21(waf1/cip1) exists as a protein complex
together with PCNA, cyclin and cdk. The data relating p21(waf1/cip1)
to cell proliferation are rather variable (Backe et al, 1997;
Aaltomaa et al, 1999b; Lipponen et al, 1998). In bladder cancer,
p21(waf1/cip1) was related to high cell proliferation, but in another
study no significant relationship could be found between these
variables (Lipponen et al, 1998). These conflicting results are most
probably due to altered stoichiometry of these proteins in malig-
nant cells, and the metabolism of p21(waf1/cip1) may be disturbed
because of an altered protein structure. Also, it is possible that
p21(waf1/cip1)-positive tumour cells represent a subpopulation of cells
that have withdrawn from the cell cycle amid the otherwise rapidly
proliferating tumour cells (El Deiry et al, 1995).
Our survival analysis showed that p21(waf1/cip1) had no prognostic
value in RCC. Similar results have been reported in bladder,
prostate, endometrium and hepatocellular cancer (Backe et al,
1997; Byrne et al, 1997; Aaltomaa et al, 1999b; Lipponen et al,
1998; Naka et al, 1998). On the contrary, in oesophageal and colon
cancer, as well as in squamous cell carcinomas of the head and
neck, the strong expression of cyclin D1 was related to
unfavourable prognosis (Ishikawa et al, 1998; Maeda et al, 1998).
In addition, in colorectal adenocarcinoma and in superficial
bladder cancer the overexpression of cyclin D1 predicts early
recurrence (Shin et al, 1997; Maeda et al, 1998). Moreover, cyclin
D1 overexpression is related to favourable prognosis in breast
cancer (Gillet et al, 1996). In RCC we found no correlation
between the expression of cyclin D1 and survival or recurrence-
free survival, whereas cyclin A was a powerful predictor of patient
outcome, and the independent prognostic value of cyclin A was
confirmed also in multivariate analyses of the various subgroups
of the tumours. If the cases were categorized into three groups –
0%, 1–5% and over 5% – of cyclin A-positive cells, the corre-
sponding survival rates at 10 years were 60%, 30% and 10%
respectively (P < 0.0001). This clearly shows that cyclin A expres-
sion can be used in categorizing RCCs into prognostic groups.
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Figure 3 The survival of RCC patients categorized according to the fraction
of cyclin A-positive cancer cells in M0 patients. The curves are significantly
separated (c2 = 11.5, P = 0.007). Curve A: the fraction of cyclin A-positive
cells ≤ 1%, n = 50; Curve B: the fraction of cyclin A-positive cells > 1%,
n = 32
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Figure 4 The survival of patients with a T1–2/N0/M0 RCC categorized
according to the fraction of cyclin A-positive cancer cells. The curves are
significantly separated (c2 = 11.4, P = 0.0007). Curve A: the fraction of cyclin
A-positive cells ≤1%, n = 29; Curve B: the fraction of cyclin A-positive cells
> 1%, n = 16Cyclin A was an important prognostic factor for recurrence-free
survival as well. Since there are no published reports available on
the prognostic value of cyclin A in other cohorts of RCC, the
comparison to our data remains to be verified in further studies.
However, there are only few prognostic studies of abnormal
expression of cyclin A in the literature and similar prognostic
results have been reported at least in squamous cell lung and
prostate cancer (Aaltomaa et al, 1999a; Volm et al, 1998).
Finally, we suggest that cyclin A expression is a valuable addi-
tional prognostic factor in all stages of RCC and might be used as
an additional prognostic criteria in defining correct prognostic
category for patients to be used in making therapy plans.
In conclusion, the expression of cyclin A was closely related to
malignant cellular features and cell proliferation in RCC. The
staining signal of cyclin D1 showed a weak inverse correlation to
indicators of cell proliferation and tumour malignancy, while the
expression of p21(waf1/cip1) was totally independent of other prog-
nostic factors. Moreover, cyclin A overexpression was indepen-
dently associated to shortened recurrence-free survival and cancer
related survival, suggesting that cyclin A is a promising prognostic
factor in renal cell carcinoma.
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